Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tussavit is a herbal cough syrup developed by Pharmazeutische Fabrik Montavit Ges.m.b.H. It is composed of fluid extracts from thyme herb (Thymus vulgaris) and ribwort plantain (Plantago lanceolata). The product is indicated for the symptomatic treatment of coughs associated with inflammatory respiratory tract diseases, such as acute and chronic bronchitis, the common cold, and respiratory infections, as well as a supportive treatment for whooping cough. Its multi-modal mechanism of action involves the expectorant properties of thyme's essential oils (specifically thymol and carvacrol), which stimulate bronchial secretion and mucociliary clearance, and the soothing, protective effects of plantain's mucilaginous substances on the bronchial mucosa. Additionally, the thyme components provide antimicrobial activity against respiratory pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tussavit.